Resource Summary Report

Generated by RRID on Sep 11, 2026

Bcl-xL (H-5)

RRID:AB_626739
Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-8392, RRID:AB_626739

Antibody Information

URL: http://antibodyregistry.org/AB_626739

Proper Citation: Santa Cruz Biotechnology Cat# sc-8392, RRID:AB_626739

Target Antigen: Bcl-xL (H-5)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: WB, IP, IF, IHC(P), FCM, ELISA; ELISA; Flow Cytometry; Immunocytochemistry; Immunoprecipitation; Immunofluorescence; Immunohistochemistry; Western Blot

Antibody Name: Bcl-xL (H-5)

Description: This monoclonal targets Bcl-xL (H-5)

Target Organism: rat, mouse, human

Antibody ID: AB_626739

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8392

Record Creation Time: 20231110T080402+0000

Record Last Update: 20260829T014718+0000

Ratings and Alerts

No rating or validation information has been found for Bcl-xL (H-5).

No alerts have been found for Bcl-xL (H-5).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Pocasap P, et al. (2025) Unveiling the Anticancer Potential and Molecular Mechanisms of Fangchinoline Against Cholangiocarcinoma Using FTIR Microspectroscopy, In Vitro and In Silico Approaches. Integrative cancer therapies, 24, 15347354251396513.

Huang H, et al. (2025) Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell population expansion. Molecular systems biology, 21(8), 1119.

Newman CE, et al. (2025) Inhibition of oligomeric BAX by an anti-apoptotic dimer. Cell, 188(26), 7397.

Tooley K, et al. (2024) Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity. Cell reports. Medicine, 5(7), 101640.

Huang H, et al. (2024) Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell proliferation. bioRxiv : the preprint server for biology.

Giampaolo S, et al. (2023) NFATc1 induction by an intronic enhancer restricts NKT ?? cell formation. iScience, 26(3), 106234.

Tsubaki M, et al. (2023) Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy. Cancer cell international, 23(1), 73.

Ming Z, et al. (2023) IFN-? Signaling Sensitizes Melanoma Cells to BH3 Mimetics. The Journal of investigative dermatology, 143(7), 1246.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer discovery, 12(3), 752.

Hattori EY, et al. (2022) A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice. Communications biology, 5(1), 939.

Roversi FM, et al. (2022) Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer immunology, immunotherapy : CII, 71(8), 1909.

Kuzuoglu-Ozturk D, et al. (2021) Revealing molecular pathways for cancer cell fitness through a genetic screen of the cancer translatome. Cell reports, 35(13), 109321.

Chen Z, et al. (2021) In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell, 184(5), 1262.

Jin J, et al. (2020) CD137 Signaling Regulates Acute Colitis via RALDH2-Expressing CD11b-CD103+ DCs. Cell reports, 30(12), 4124.

Guièze R, et al. (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer cell, 36(4), 369.

Vanaja KG, et al. (2018) A Loss of Epigenetic Control Can Promote Cell Death through Reversing the Balance of Pathways in a Signaling Network. Molecular cell, 72(1), 60.

Jin L, et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell, 34(2), 315.